Consensus is for FY24 revenue $636.59M. The updated range represents a 3% decrease from the FY23 revenue at the midpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- TXG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PacBio includes Onso platform in 10x Genomics Compatible Partner Program
- UPC rules in favor of Bruker and NanoString invalidating 10x Genomics patent
- 10x Genomics price target lowered to $21 from $24 at Barclays
- Cathie Wood’s ARK Investment buys 1.15M shares of 10x Genomics today